Skip to main content
Clinical Trials/ACTRN12623000360617
ACTRN12623000360617
Recruiting
未知

A Clinical Pilot, Prospective, Participant and Observer-Blinded, Sham-Controlled, Randomised, Dose-Response Study Investigating Focused Ultrasound for Temporary Pain Relief in Moderate-to-Severe Knee Osteoarthritis

Pegasus Neurotechnology0 sites16 target enrollmentApril 12, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Knee Osteoarthritis
Sponsor
Pegasus Neurotechnology
Enrollment
16
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 12, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Pegasus Neurotechnology

Eligibility Criteria

Inclusion Criteria

  • 1\. Adults \>\= 18 years of age with Medicare coverage.
  • 2\. Participants with medial knee osteoarthritis, where:
  • a) Knee osteoarthritis is defined according to American College of Rheumatology criteria (knee pain, aching or stiffness on most of the past 30 days and evidence on radiograph of knee osteoarthritis).
  • b) Participants have evidence of disease in the medial compartment on a radiograph, where evidence of disease in the medial compartment in radiographs is defined as at least grade 2 on the Kellgren and Lawrence system.
  • 3\) Knee pain of at least 5 out of 10 when performing one of two movements that elicit the worst pain: standing from a seated position and a slow squat (90 degrees).
  • 4\) Knee pain is reported in the medial knee as documented on the knee pain map.
  • 5\) A diagnostic nerve block of the infrapatellar branch of the saphenous nerve results in a \>\=50% reduction in the NRS pain assessment score in knee pain when performing the activity that elicits the worst pain: standing from a seated position or a slow squat (90 degrees).
  • 6\) Stable use of prescription and over\-the\-counter pain medication for \>\=1 month.
  • 7\) Ambulatory without assistive devices.
  • 8\) An ability to read and speak English fluently.

Exclusion Criteria

  • 1\. Planned knee replacement within the next 3 months in the knee to be treated.
  • 2\. Viscosupplementation, intra\-articular steroid injection, acupuncture or percutaneous electrical nerve stimulation within the previous 3 months in the knee to be treated.
  • 3\. Previous radiofrequency ablation or cryotherapy in the knee to be treated.
  • 4\. Prior surgery in the treatment area that may alter the anatomy of the saphenous nerve or result in scar tissue in the skin or soft tissue overlying the treatment area.
  • 5\. Prior knee replacement surgery or open knee surgery in the knee to be treated.
  • 6\. Prior trauma or fractures within the previous 12 months in the knee to be treated.
  • 7\. Open and/or infected wound in the treatment area.
  • 8\. Participant reports the majority of knee pain to be outside of the medial aspect of the knee.
  • 9\. Use of opioids within the previous 3 months or previous history of opioid abuse.
  • 10\. Body Mass Index \>\= 39 kg/m2

Outcomes

Primary Outcomes

Not specified

Similar Trials